Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, USA.
Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA.
J Interferon Cytokine Res. 2020 Dec;40(12):543-548. doi: 10.1089/jir.2020.0214.
The coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), warranting urgent study of the molecular mechanisms of SARS-CoV-2 infection and host immune response. Type I interferon (IFN-I) is a key component of host innate immune system responsible for eliminating the virus at the early stage of infection. In contrast, SARS-CoV-2 has evolved multiple strategies to evade innate immune response to facilitate viral replication, transmission, and pathogenesis. This review summarizes the recent progresses on SARS-CoV-2 proteins that antagonize host IFN-I production and/or signaling. These progresses have provided knowledge for new vaccine and antiviral development to prevent and control COVID-19.
新型冠状病毒病（COVID-19）大流行是由严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起的，迫切需要研究 SARS-CoV-2 感染和宿主免疫反应的分子机制。I 型干扰素（IFN-I）是宿主固有免疫系统的关键组成部分，负责在感染的早期阶段消除病毒。相比之下，SARS-CoV-2 已经进化出多种策略来逃避固有免疫反应，以促进病毒复制、传播和发病机制。这篇综述总结了 SARS-CoV-2 蛋白拮抗宿主 IFN-I 产生和/或信号转导的最新进展。这些进展为预防和控制 COVID-19 的新型疫苗和抗病毒药物的开发提供了知识。
